FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study ; volume:14 ; number:1 ; day:14 ; month:6 ; year:2014 ; pages:1-8 ; date:12.2014
BMC cancer ; 14, Heft 1 (14.6.2014), 1-8, 12.2014
- Creator
-
Zaanan, Aziz
- Contributor
-
Trouilloud, Isabelle
Markoutsaki, Theofano
Gauthier, Mélanie
Dupont-Gossart, Anne-Claire
Lecomte, Thierry
Aparicio, Thomas
Artru, Pascal
Thirot-Bidault, Anne
Joubert, Fanny
Fanica, Daniella
Taieb, Julien
SpringerLink (Online service)
- DOI
-
10.1186/1471-2407-14-441
- URN
-
urn:nbn:de:1111-2016030421048
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 15.08.2025, 7:19 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Zaanan, Aziz
- Trouilloud, Isabelle
- Markoutsaki, Theofano
- Gauthier, Mélanie
- Dupont-Gossart, Anne-Claire
- Lecomte, Thierry
- Aparicio, Thomas
- Artru, Pascal
- Thirot-Bidault, Anne
- Joubert, Fanny
- Fanica, Daniella
- Taieb, Julien
- SpringerLink (Online service)
Other Objects (12)
Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer
Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer
Current standard and future perspectives in first- and second-line treatment of metastatic pancreatic Adenocarcinoma
Hypofractionated radiotherapy plus PD-1 antibody and SOX chemotherapy as second-line therapy in metastatic pancreatic cancer: a single-arm, phase II clinical trial
Cost-effectiveness of pembrolizumab versus chemotherapy in patients with platinum-pretreated, recurrent or metastatic nasopharyngeal cancer
Cross-over comparison and new chemotherapy regimens in metastatic pancreatic cancer
Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer
FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort
A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma
Gemcitabine and Carboplatin in Intensively Pretreated Patients with Metastatic Breast Cancer
177 Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated with Chemotherapy: Analysis of Outcome, Safety, and Their Determinants
Second-line tislelizumab versus chemotherapy in Japanese patients with advanced or metastatic esophageal squamous cell carcinoma: subgroup analysis from RATIONALE-302
Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer
Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer
Current standard and future perspectives in first- and second-line treatment of metastatic pancreatic Adenocarcinoma
Hypofractionated radiotherapy plus PD-1 antibody and SOX chemotherapy as second-line therapy in metastatic pancreatic cancer: a single-arm, phase II clinical trial
Cost-effectiveness of pembrolizumab versus chemotherapy in patients with platinum-pretreated, recurrent or metastatic nasopharyngeal cancer
Cross-over comparison and new chemotherapy regimens in metastatic pancreatic cancer
Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer
FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort
A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma
Gemcitabine and Carboplatin in Intensively Pretreated Patients with Metastatic Breast Cancer
177 Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated with Chemotherapy: Analysis of Outcome, Safety, and Their Determinants
Second-line tislelizumab versus chemotherapy in Japanese patients with advanced or metastatic esophageal squamous cell carcinoma: subgroup analysis from RATIONALE-302
Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer
Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer
Current standard and future perspectives in first- and second-line treatment of metastatic pancreatic Adenocarcinoma
Hypofractionated radiotherapy plus PD-1 antibody and SOX chemotherapy as second-line therapy in metastatic pancreatic cancer: a single-arm, phase II clinical trial
Cost-effectiveness of pembrolizumab versus chemotherapy in patients with platinum-pretreated, recurrent or metastatic nasopharyngeal cancer
Cross-over comparison and new chemotherapy regimens in metastatic pancreatic cancer
Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer
FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort
A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma
Gemcitabine and Carboplatin in Intensively Pretreated Patients with Metastatic Breast Cancer
177 Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated with Chemotherapy: Analysis of Outcome, Safety, and Their Determinants